CAR T Cell Therapy News

News Image

City of Hope is now enrolling patients with multiple myeloma whose disease has relapsed, or is treatment-resistant, for a first-of-its kind chimeric antigen receptor (CAR) T cell therapy trial. It will also manufacture CAR T cells in its own laboratories.

test tubes

City of Hope’s clinical trials program is special because it was built with the same core values as the institution itself: an emphasis on leading-edge medicine, compassionate care, rapid bench-to-bedside research and always putting the patient first.


Blood Cancer | City of Hope

City of Hope is now enrolling relapsed/refractory multiple myeloma patients for a first-of-its kind chimeric antigen receptor T cell therapy phase I trial.


Michael Caligiuri

City of Hope will showcase ongoing studies and data on chimeric antigen receptor (CAR) T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research annual meeting from March 29 through April 3 in Atlanta.


News Image

City of Hope will showcase ongoing studies and data on chimeric antigen receptor (CAR) T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research (AACR) annual meeting from March 29 through April 3 in Atlanta.

News Image

Stephen J. Forman, M.D., the renowned leader of the Hematologic Malignancies and Stem Cell Transplantation Institute and the Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, will receive the 2019 DKMS Mechtild Harf Science Award in honor of his outstanding achievements in cancer immunology, hematology, stem cell transplantation and CAR T cell therapy.

Rare Disease Day | City of Hope

City of Hope has long been renowned for its expertise in treating cancer and diabetes. But specialists here also are tackling lesser-known but equally devastating diseases that may or may not have an oncologic component.


News Image

An international leader in finding new, innovative treatments for lymphoma patients, City of Hope announced today that it has received its third lymphoma Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI), one of four current NCI-supported lymphoma SPOREs. The grant covers a five-year period and totals $12.5 million.

Lauren Lugo | City of Hope

Vanessa Jonsson, Ph.D., focuses on chimeric antigen receptor (CAR) T cell therapy. Using such tools as computational analysis and mathematical modeling, she examines the complex interactions between the tumor, the patient’s immune system and the therapy to learn how the tumor evades the immune response.


CAR T Nurses | City of Hope

What's it like to work at the center of a true medical and scientific revolution? It's emotional, often overwhelming. But it’s also a place to witness miracles. Such is the life of the clinical research nurses who staff City of Hope's CAR T cell program.


Cheryl Wiers CAR T | City of Hope

Meet float rider Cheryl Wiers, a wife and mother of two who battled cancer twice only to have it return. She eventually found prolonged remission thanks to a CAR T Cell therapy offered at City of Hope.


red and white blood cells

City of Hope clinical and laboratory investigators presented leading-edge research, including new targets in CAR T cell therapy, at the 60th annual ASH meeting in San Diego.


Xiuli Wang 300x300

Xiuli Wang, Ph.D., research professor at City of Hope, presented encouraging research on using CAR T cell therapy for central nervous system lymphoma at this year's American Society of Hematology conference.


red and white blood cells

Physicians and researchers at the 2018 American Society of Hematology conference presented clinical trials for new leukemia and lymphoma treatments, laying the groundwork for innovative therapeutic approaches aimed at improving treatment options and quality of life for patients.